Schrodinger Reports Q4 Net Income, Strong FY25 Revenue Growth, and Targets Positive Adjusted EBITDA by 2028
summarizeSummary
Schrodinger reported a profitable Q4 2025, strong full-year revenue growth, and is strategically shifting to a hosted software model while targeting positive adjusted EBITDA by 2028.
check_boxKey Events
-
Fourth Quarter 2025 Profitability Turnaround
The company reported net income of $32.5 million for the fourth quarter of 2025, a significant improvement compared to a net loss of $40.2 million in the same period of 2024.
-
Strong Full Year 2025 Revenue Growth
Total revenue for the full year 2025 increased by 23.3% to $255.9 million, with software revenue growing 10.6% to $199.5 million and drug discovery revenue more than doubling to $56.4 million.
-
Strategic Shift to Hosted Software Model
Schrodinger is accelerating its transition to hosted software solutions, which will shift revenue recognition from upfront to ratable. This is expected to lead to more predictable revenue streams, without impacting ACV or cash flow, despite potential short-to-medium term GAAP revenue declines.
-
2026 Outlook and 2028 Financial Objectives
For 2026, software ACV is projected to grow 10-15% to a range of $218 million to $228 million. The company aims to achieve positive adjusted EBITDA by the end of 2028.
auto_awesomeAnalysis
Schrodinger, Inc. reported a significant improvement in its financial performance, achieving net income of $32.5 million in Q4 2025, a substantial turnaround from a net loss in the prior year. For the full year 2025, total revenue increased by 23.3% to $255.9 million, and the net loss was significantly reduced. The company also announced a strategic acceleration of its transition to a hosted software model, which is expected to create a more predictable, ratable revenue stream, although it may cause short-to-medium term declines in GAAP software revenue. This shift will not impact Annual Contract Value (ACV) or cash flow. Management's commitment to achieving positive adjusted EBITDA by the end of 2028, coupled with a strong cash position, provides a clear path for future financial stability and growth.
At the time of this filing, SDGR was trading at $11.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $869.2M. The 52-week trading range was $11.11 to $27.63. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.